drugset / Trial / NCT07154264

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

NCT07154264

Phase 2 Recruiting 66 enrolled Dizal Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.

Timeline

Start
2025-09-22
Primary completion
2029-12
Completion
2030-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DZD8586 Unknown Oral
Subject Venetoclax Small molecule Oral